ALKERMES | ALKS - Debt

ALKERMES reported $293.27M in Debt for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Debt Change
Acorda Therapeutics ACOR:US USD 167.03M 20.66M
Amgen AMGN:US USD 38.94B 241M
Biogen BIIB:US USD 6.28B 1.8M
Biomarin Pharmaceutical BMRN:US USD 1.09B 3.46M
Bristol Myers Squibb BMY:US USD 39.32B 222M
Coherus Biosciences CHRS:US USD 473.67M 3.17M
Heron Therapeutics HRTX:US USD 149.28M 50K
Horizon Pharma HZNP:US USD 2.56B 2.3M
IONIS PHARMACEUT IONS:US USD 1.19B 64.22M
JAZZ PHA JAZZ:US USD 5.72B 2.47M
Marinus Pharmaceuticals MRNS:US USD 71.02M 238K
Neurocrine Biosciences NBIX:US USD 169.4M 200K
Otsuka Holdings 4578:JP JPY 194.16B 11.4B
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Revance Therapeutics RVNC:US USD 380.04M 8.24M
Teva Pharmaceutical Industries TEVA:US USD 21.21B 54M
Vertex Pharmaceuticals VRTX:US USD 471.6M 29.3M